Skip to content
About
Supporter
Expert Index
Editorial Board
Editorial Team
Editorial Policy
Contact
Sign up
Visit
Home
(current)
Diseases
Parkinson's Disease
Multiple Sclerosis and Related Disorders
Headache
Amyotrophic Lateral Sclerosis
Epilepsy
Sleep Disorders
Stroke
Neuromuscular Disorders
Movement Disorders
View all Diseases
Topics
Biology
Diagnostics
Trial Updates
Treatment
Prevention
Surgery
Imaging
Genetics
COVID-19
View all Topics
Conferences
EAN 2022
ESOC 2022
AAN 2022
CONy 2022
AD/PD 2022
World Sleep 2022
View all Conferences
Features
Podcasts
About
Supporter
Expert Index
Editorial Board
Editorial Team
Editorial Policy
Contact
Sign up
Teriflunomide
3:15
Humoral and cellular responses to SARS-CoV-2 vaccination in patients with MS treated with DMTs
Virginia Meca-Lallana
• 28 Feb 2022
1:11
Comparative effectiveness and persistence of cladribine versus other oral DMTs in MS
Namita Tundia
• 25 Feb 2022
1:57
COVID booster vaccines do not lead to humoral responses in patients with MS treated with DMTs
Celia Oreja-Guevara
• 24 Feb 2022
3:26
Phase III ULTIMATE I & II update: ublituximab versus teriflunomide in relapsing MS
Lawrence Steinman
• 15 Oct 2021
1:41
Ublituximab: pending approval for relapsing MS
Lawrence Steinman
• 15 Oct 2021
6:28
Humoral response to COVID-19 vaccination in patients with MS
Celia Oreja-Guevara
• 14 Oct 2021
3:27
ULTIMATE I & II results: ublituximab versus teriflunomide in relapsing MS
Lawrence Steinman
• 11 Jun 2021
1:46
Managing pediatric MS in the current era
Tanuja Chitnis
• 26 Apr 2021
2:13
Is long-term teriflunomide treatment safe in MS?
Mark Freedman
• 3 Mar 2021
2:12
TERIKIDS study: teriflunomide in pediatric patients with relapsing MS
Tanuja Chitnis
• 24 May 2020